Announced Wed, 1 Apr · 16:25 IST
Piramal Pharma completes Kenalog® acquisition from Bristol-Myers Squibb
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹142.50
prior close
₹140.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-1.7-2.2-2.0+0.9-1.0+1.2+0.7+2.5+4.2+18.6+12.6+17.4+18.4
Up moveDown movePending
AI summary
Piramal Pharma's step-down wholly owned subsidiary, Piramal Critical Care B.V., has completed the acquisition of Kenalog®, a branded commercial injectable product, and its associated brands from Bristol-Myers Squibb Company. The deal, first announced on 28 January 2026, strengthens Piramal's Complex Hospital Generics portfolio and expands its presence in the United States, Europe, and Asia Pacific markets.
Likely market impact
Expands complex hospital generics portfolio across US, Europe, and APAC — likely positive for revenue diversification and growth.